Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Crockett (NPI 1801107636)

Field	Value
Entity Type	Individual
Organization	David Crockett
Address	985100 Nebraska Medical Ctr
City	Omaha
State	NE
ZIP	68198
Taxonomy	Internal Medicine Physician
NPI Enumerated	June 26, 2010

Payer Source	Total Paid
Medicare	$982.8K
Medicaid	$0

Key Findings

This provider’s billed Medicare activity is concentrated: total Medicare revenue is $982.8K and there is no Medicaid billing on file, making the practice effectively single‑payer (Medicare) in scope. The precomputed metric notes that the top three Medicare codes account for 81.3% of Medicare revenue, underscoring a narrow revenue base tied to a small set of services and drugs.

Revenue is heavily dominated by one oncology drug line: J9271 (pembrolizumab) accounts for $619.2K and 63.7% of the provider’s Medicare revenue, while the next two top codes are 99214 ($89.2K, 9.2%) and J0897 ($82.1K, 8.4%). Because the top three codes together represent 81.3% of Medicare revenue, the practice’s financial performance is highly dependent on continued pembrolizumab utilization and reimbursement.

The code mix indicates an infusion/oncology-focused operation rather than a general primary care clinic: high-revenue J9271 and J0897 entries plus chemotherapy administration codes such as 96413, 96401 and add-on infusion codes (96417, 96411, 96415) point to in‑office administration of immunotherapy and antineoplastic agents. Supporting codes for IV infusions (96365, 96367, 96375) and iron infusions (J1439) further corroborate an infusion therapy service line with adjacent procedural support.

Competitive standing is mixed by code. For pembrolizumab (J9271) the provider ranks #729 of 1841 nationally (60th percentile), described as typical and unremarkable volume, and for denosumab (J0897) ranks #3091 of 10057 (69th percentile), also typical; by contrast the E/M code 99214 ranks #11376 of 479517 (98th percentile) and is labeled notably above typical national volume, indicating the practice sees an unusually high volume of moderate-complexity established-patient office visits compared with national peers.

Ancillary service volumes reinforce an infusion practice model: 36415 (venipuncture) shows 765 claims, $6.1K revenue and ranks #4857 of 86467 (94th percentile), consistent with above-typical phlebotomy throughput needed for infusion monitoring. Multiple infusion/administration codes (96365: 165 claims; 96413: 339 claims; 96401: 139 claims) appear in the top-25 list, showing routine procedural billing alongside high-cost drug administration.

Payer concentration poses an operational risk: with $982.8K in Medicare revenue and explicitly “none below” for Medicaid, the provider lacks Medicaid diversification and is exposed to Medicare policy changes and beneficiary population shifts. This single-payer orientation should be considered when assessing reimbursement vulnerability and growth opportunities.

The provider’s NPI was enumerated on 2010-06-26 (~16 years ago), indicating a long-established billing history under this NPI. Combined with sustained high-dollar drug billing (e.g., ongoing J9271 activity), the tenure suggests a stable, continuing infusion/oncology practice rather than a recent or transient entrant into high-cost drug administration.

Most high-revenue lines are described as typical in national comparisons, except for E/M visits and certain procedural volumes: 99214 is “notably above typical national volume,” and several procedural codes (e.g., 36415 at the 94th percentile and 99215 at the 85th percentile) are above typical, while high-cost drug codes like J9271 are in the middle of the national distribution (60th percentile). This pattern signals a practice that pairs average-to-typical drug administration volumes with higher-than-typical outpatient visit and ancillary procedure throughput.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

42 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	14,400	$40	$619.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,000	$90	$89.2K
J0897	Injection, denosumab, 1 mg	4,560	$20	$82.1K
J1439	Injection, ferric carboxymaltose, 1 mg	31,500	$1	$31.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	340	$90	$31.2K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	8,950	$1	$17.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	130	$130	$16.9K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	110	$130	$14.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	160	$60	$9.5K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	60	$160	$8.8K

Showing 1–10 of 42

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 42 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

David Crockett — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

42 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	30	14,400	$40	$671.6K
J0897	41	200	2,040	$20	$62.7K
J0881	12	10	17,260	$1	$54.5K
J1439	11	30	25,880	$1	$26.4K
J9217	27	50	110	$130	$20.6K
96413	21	80	60	$90	$18.2K
99214	73	3,210	110	$70	$14.9K
96401	14	30	120	$50	$11K
99213	970	3,220	90	$50	$7.9K
99215	118	920	40	$110	$7K

Showing 1–10 of 42

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Crockett, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Robert Langdon	NE	Hematology & Oncology Physician	$1.4M	$0
Muhammad Haroon	NE	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as David Crockett, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The Nebraska Medical Center	NE	General Acute Care Hospital	$0	$76.5M
Unmc Physicians	NE	Multi-Specialty Clinic/Center	$0	$41.1M
Unmc College Of Dentistry	NE	Dentist	$0	$974.6K
Amanda Dimmitt	NE	Diagnostic Radiology Physician	$287.6K	$0
Joel Brink	NE	Diagnostic Radiology Physician	$285.8K	$0
Han Kim	NE	General Practice Dentistry	$0	$285.8K
Shahid Hussain	NE	Diagnostic Radiology Physician	$201.7K	$32.5K
Brent Timperley	NE	Ophthalmology Physician	$204.9K	$0
Chris Cornett	NE	Orthopaedic Surgery Physician	$203K	$0
Jeffrey Klug	NE	Diagnostic Radiology Physician	$192.7K	$0

David Crockett — Billing Profile & Reimbursement Data

Sign up for David Crockett — Billing Profile & Reimbursement Data policy alerts

David Crockett — Billing Profile & Reimbursement Data

Sign up for David Crockett — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References